Cytokinetics Inc
CYTK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061983
In the last 90 days, Cytokinetics Inc insiders filed 0 open-market purchases and 16 sales; 482 institutions reported holding it in 13F filings for Q2 2026, worth $13.7B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Cytokinetics Inc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 278
- +4 vs. Q3 2022
- Shares held
- 106.3M
- +1.72M (+1.6%) vs. Q3 2022
- Total value
- $4.88B
- −$197.9M (−3.9%) vs. Q3 2022
- New holders
- 38
- 109 more added
- Sold out
- 34
- 83 more reduced
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 482 | $13.7B |
| Q1 2026 | 441 | $9.63B |
| Q4 2025 | 431 | $8.87B |
| Q3 2025 | 381 | $7.75B |
| Q2 2025 | 312 | $4.55B |
| Q1 2025 | 356 | $5.48B |
| Q4 2024 | 347 | $6.18B |
| Q3 2024 | 348 | $7.20B |
| Q2 2024 | 344 | $7.34B |
| Q1 2024 | 390 | $8.26B |
| Q4 2023 | 347 | $9.54B |
| Q3 2023 | 251 | $3.22B |
| Q2 2023 | 253 | $3.55B |
| Q1 2023 | 263 | $3.83B |
| Q4 2022 | 278 | $4.88B |
| Q3 2022 | 276 | $5.08B |
| Q2 2022 | 263 | $4.16B |
| Q1 2022 | 240 | $3.52B |
| Q4 2021 | 250 | $4.16B |
| Q3 2021 | 211 | $3.22B |
| Q2 2021 | 191 | $1.50B |
| Q1 2021 | 193 | $1.74B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Cytokinetics Inc; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −5,748−100.0% | Sold out |
| Pearl River Capital, LLC | 0 | $0 | 0.00% | −5,341−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −5,064−100.0% | Sold out |
| Mizuho Securities USA LLC | 0 | $0 | 0.00% | −4,947−100.0% | Sold out |
| Evergreen Capital Management LLC | 0 | $0 | 0.00% | −4,217−100.0% | Sold out |
| Intrust Bank NA | 0 | $0 | 0.00% | −4,163−100.0% | Sold out |
| Advisor Partners II, LLC | 0 | $0 | 0.00% | −4,156−100.0% | Sold out |
| Evoke Wealth, LLC | 0 | $0 | 0.00% | −505−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −263−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −265−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |
| FourThought Financial, LLC | – | – | – | – | Not filed |